Arboscello E, Botta M, Romero D, Schenone E, Mencoboni M, Bogliolo G, Pannacciulli I
Department of Internal Medicine (DIMI), University of Genoa, Genoa, Italy.
Anticancer Res. 2001 Mar-Apr;21(2A):1139-43.
Association of all-trans retinoic acid (ATRA) and amifostine (AMF) might be an alternative in treatment of myelodisplatic syndromes. In this study we undertook a preliminary in vitro research on the effects of a combination of ATRA and AMF on normal hemopoietic progenitors. Mononuclear, non-adherent cells from peripheral blood of normal volunteers, were incubated with AMF, at a the concentration of 500 microM and then cultured for CFU-GM and BFU-E growth adding to culture dishes before gelling ATRA at the concentration 10(-6) and 10(-12)M. Controls were cultures not pre-incubated with AMF, cultures incubated with AMF without addition of ATRA and cultures without addition of any drug. ATRA addition did not have significant effects on hemopoietic progenitors growth. Association of ATRA and AMF do not appear to synergize to stimulate in vitro growth of hemopoietic progenitors.
全反式维甲酸（ATRA）与氨磷汀（AMF）联合使用可能是治疗骨髓增生异常综合征的一种替代方法。在本研究中，我们对ATRA与AMF联合使用对正常造血祖细胞的影响进行了初步体外研究。正常志愿者外周血中的单核非贴壁细胞，先与浓度为500微摩尔的AMF孵育，然后在培养皿凝固前加入浓度为10^(-6)和10^(-12)摩尔的ATRA，用于CFU-GM和BFU-E生长培养。对照组为未预先与AMF孵育的培养物、与AMF孵育但未添加ATRA的培养物以及未添加任何药物的培养物。添加ATRA对造血祖细胞生长没有显著影响。ATRA与AMF联合使用似乎不会协同刺激造血祖细胞的体外生长。
